Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Meroni
L
L
Manganaro
D
D
Varchetta
S
S
Gatti
N
N
Riva
A
A
Monforte
A D
AD
Galli
M
M
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D019040:E-Selectin / Q000032:analysis; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins; D009244:NAD+ Nucleosidase / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015703:Antigens, CD; D000943:Antigens, Differentiation; D019040:E-Selectin; D008562:Membrane Glycoproteins; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D017493:Leukocyte Common Antigens; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1